Formed in 2016 when Omnis Pharma, Inc. and Magnis Therapeutics, LLC, - developing proprietary oncolytic virus therapies for the treatment of cancers with significant unmet needs - combined their two pipelines to include Phase II product candidates in ovarian cancer and multiple myeloma, and Phase I programs in glioblastoma, mesothelioma, head and neck cancer, blood cancers, endometrial cancer, hematologic malignancies, and gastrointestinal cancer. Structured around development of the next generation of targeted cancer therapies using engineered viruses that selectively attack cancer cells and ignite robust immune responses to prevent cancer recurrence, the potentially life-changing oncolytic viral technologies of Vyriad are the result of decades of research by dedicated researchers and clinicians at Mayo Clinic and the University of Miami.
